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Abstract
Calcitonin (Ct) is a tumour marker essential for the diagnosis and follow-up of medullary thyroid cancer (MTC).
Accurate and consistent measurements of serum Ct are of critical importance. Ct measurements by different
methods can differ, leading to difficulties in the interpretation of results. Second generation assays for Ct have
been developed and are now available in clinical laboratories. However, the lack of standardization for Ct assays
remains a common problem with Ct assays. The reference interval and reliability should be carefully defined.
The role of stimulated Ct for the diagnosis and follow-up of MTC should also be pointed out as the pentagastrin
test is no more available in all countries. However, the stimulated test remains very useful to exclude MTC if the
basal Ct serum level is in the grey zone (15-20 ng/L), after surgery to confirm the complete cure. A residual
response after surgery could indicate a need for aggressive surgery or - in case of metastatic disease - could
suggest the prognosis.
High-dose Ca test (2.5mg/kg) seems to be a reliable and effective test for the diagnosis and follow-up of MTC. It
seems more potent than pentagastrin with fewer side effects. The threshold able to discriminate healthy subjects
from C-cell hyperplasia (CCH) cases for the stimulated Ct concentration is 184 ng/L for women and 1620 ng/L for
men.
As stimulated Ca test will eventually replace the pentagastrin test, there is a need to confirm or to modify the
threshold identified for each assay individually.
Introduction
Medullary thyroid carcinoma (MTC) originates from
thyroid C cells, which secrete calcitonin (Ct).
Routine measurement of Ct in patients with nodular
goitre allows for the preoperative diagnosis of unsuspected
MTC, often at a very precocious stadium.
Ct is a 32 amino- acid- polypeptide, in which the disul-
phide bridges are essential for biological activity. The phy-
siological role of Ct is unknown. The C cells use the same
calcium receptor as do parathyroid cells [1], and high cal-
caemia is their physiological stimulant. Non physiological
stimulants include glucagon, b-adrenergic agonists, alco-
hol, and gastrin [2].
Basal calcitonin
Accurate and consistent measurements of serum Ct are
of critical importance. Ct values measured by different
methods can differ, leading to difficulties in interpreta-
tion of results
Since 1988, RIA with polyclonal antibodies that
recognised both mature Ct monomer and other circu-
lating forms lacking specificity and sensibility, have
been used. Second generation automated immunoas-
says with more specific antibodies are now available
for clinical laboratories.
Minimal and mild elevations in serum Ct may be seen in
C-Cells hyperplasia, renal failure, autoimmune thyroiditis,
and hypercalcaemia. Elevated Ct levels may result from
non thyroid neuroendocrine tumours. Falsely low Ct levels
may occur in the setting of heterophilic antibodies and
from a “hook effects”. Optimally, an individual should be
followed using the same Ct assay over time and the
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laboratory should report which Ct assay is being used. Ct
values should also be interpreted in the setting of gender
specific reference intervals. Moreover, caution has to be
taken in interpreting values in children younger than 3
years.
The effort of standardization for some thyroid related
assays is on-going; nevertheless Ct assays remain yet not
standardized [3]. Table 1 summarizes the Ct assay perfor-
mances and data provided by the manufactures. Therefore,
the reference interval for a healthy population as well as
the reliability should be clearly defined for every Ct assay.
The American Thyroid association guidelines do not spe-
cify any reference range for Ct but several recent reports
have proposed some cut-off points for Ct testing.
Doyle reported [4] that the basal Ct (measured by a two-
site automated chemiluminescent immunometric assay)
was 5 ng/L for men and 5.7 ng/L for women (95th percen-
tile). Rink [5] found that the basal Ct level was 32.9 ng/L
for men and 14.6 ng/L for women.
An upper limit of 15 ng/L should be able to rule out
MTC and reduce false positive cases [5]. In the range
between 15-50 ng/L, the predictive value for detection of
MTC was 4%. d’Herbomez et al. [6] suggested a 20 ng/L
threshold to limit false positive results and a second con-
trol. Colombo et al. [7] demonstrated that the best levels
of basal Ct (assayed by chemiluminescence, Immulite
2000) to separate healthy subjects and CCH cases from
MTC patients were above 18.7 ng/L in females and above
68 ng/L in males.
However, the question arises whether the decision-
making can be reliably based on a single basal Ct
measurement for diagnosis in patients with a genetic sus-
ceptibility to develop MTC (i.e., activated RET oncogene-
carriers) or for the follow-up after surgery for a known
MTC. This strategy was recently recommended by the
American thyroid association as the pentagastrin is now
unavailable in many countries [8]. However, even if the
ultrasensitive Ct assay will reduce the false negative rate
of basal Ct measurements when diagnosing familial MTC
and in post-operative follow-up, compared to previously
used assays, it has recently been shown that its sensitivity
to detect C-cell disease remains lower than a stimulation
test [9].
Indications of calcitonin stimulation tests
The role of stimulated Ct for the diagnosis and follow-
up of MTC has recently been pointed out since the clas-
sical pentagastrin test is no more available in some Eur-
opean countries.
The stimulation test remained very useful to exclude an
MTC in an unaffected individual when basal Ct was in
the grey zone (15-50 ng/L) as observed in autoimmune
thyroiditis with CCH or in neuroendocrine tumours.
Another indication for the stimulation test was to detect
residual disease or recurrence after surgery for MTC in
patients with low basal Ct levels. Patients who have non-
detectable and non-stimulable post-operative Ct at two
consecutive follow-up visits are considered disease-free,
although they still require yearly follow-up assessments
as late recurrence of disease can occur, and there might
thus be a need for future complementary surgery. How-
ever, it must be remembered that the volume of residual
disease is usually very low when only the stimulated Ct
level is detectable, and unlikely to be found by imaging
until basal Ct is over 150 ng/L [10]. In case of metastatic
disease, the response and the peak value could also be
indicative of the prognosis. Finally, in genetically predis-
posed patients with intermediate or low-risk RET proto-
oncogene mutations, a prophylactic thyroidectomy is
usually advised if basal Ct is lower than 10 ng/L and peak
Ct (following pentagastrin stimulation test) is between 50
and 100 ng/L.
Pentagastrin stimulation test
The pentagastrin stimulation test uses a slow intravenous
injection of pentagastrin (0.5 µg/kg body weight) over
three minutes. Blood samples are obtained at baseline,
and two and five minutes after pentagastrin injection.
The cut-off of the pentagastrin-stimutated Ct is still
not clear in the literature and depends on the assay
Table 1 Calcitonin assays performances
Assay Format Sample
volume
Pretreatment Within-run CV Between-run CV Measuring
range
LLD
Cis-bio RIA 200µl 30 min 56°C 6.7% at 10.9 ng/L 5.2% at 21.1 ng/L 1.5 –1530 ng/L 1.5 ng/L
Diasorin Automated chemi-
luminescent
150µl NO 2. 5% at 25 ng/L 3.1% at
160 ng/L
5% at 25 ng/L 4.7% at
160 ng/L
1.0 – 2000 ng/L 4 ng/L
Siemens Automated chemi-
luminescent
200 µl NO 3.4% at 29 ng/L 2.3% at
200 ng/L
4.2% at 29 ng/L 5.5% at
260 g/L
2.0 – 2000 ng/L 2 ng/L
IBL ELISA 100 µl NO 2.8% at 37 ng/L 2.4% at
260 ng/L
8.6% at 41 ng/L 6.3% at
167 ng/L
1.3 – 790 ng/L 1.3 ng/L
DSL IRMA 150 µL NO 2.4% at 27 ng/L 5.1% at
390 ng/L
9.0% at 24.3 ng/L 7.8% at
391 ng/L
5 – 500 ng/L 5 ng/L
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used. Verga et al. [11] showed that a peak above 50ng/L
indicated a risk of CCH and MTC, while Scheuba et al.
[12] found that the probability of having an MTC was
100% if the peak value was higher than 560 ng/L; finally,
Elisei et al. [13] determined the lowest peak of Ct for
MTC to be 118 ng/L. In chronic renal disease, the peak
may reach 400 ng/L. In 2002, the National Academy of
Clinical Biochemistry (NACB) has documented that 80%
of healthy subjects have a Ct peak lower than 10 ng/L,
15% have a peak between 10 and 30 ng/L and 5% may
have a peak between 30 and 50 ng/L [14]. When the peak
stimulated Ct was between 50 and 100 ng/L, the risk of
diagnosis of C-cell pathology is intermediate and a peak
higher than 100 ng/L likely indicates CCH or MTC.
In a recent study, a peak Ct of 275 ng/L determined by
IRMA after pentagastrin was able to clearly distinguish
patients with MTC from patients with CCH with 100%
sensitivity and 89% specificity [15].
It therefore appeared that if stimulated Ct (sCt) values
were higher than 200 ng/L, MTC was likely and thyroi-
dectomy and lymphadenectomy required. If sCt reached
values between 100 and 200 ng/L, the risk was uncertain.
Such values could be indicative of C cell hyperplasia or
microscopic MTC. Some would advise surgery, others
preferred observation.
The calcium stimulation test
Due to the unavailability of pentagastrin in many coun-
tries, there is a growing interest in the calcium stimulation
test.
This test uses an infusion of calcium gluconate (2.5 mg
elemental calcium/kg body weight) over 30 seconds admi-
nistered in fasting state. Blood samples for Ct are obtained
at baseline and two and five minutes after the stimulus.
High-dose calcium is more effective and a better-tolerated
Ct stimulator than pentagastrin.
There are very few data using the calcium stimulation as
a confirmatory test in patients with C-cell disease. Cut-off
points for the discrimination of healthy subjects, C cell
hyperplasia and MTC cases have not been standardized
yet. In one study [4] the levels of Ct stimulated after either
pentagastrin or calcium were significantly correlated. In
this study, calcium stimulated Ct levels above 32.6 ng/L
(females) and 192 ng/L (males) had the best accuracy to
differentiate normal subjects from patients with C cell
hyperplasia and MTC and values above 184 ng/mL in
females and above 1620 ng/L in males had the highest
accuracy to distinguish healthy subjects and CCH cases
from the patients with MTC.
The criteria for abnormal Ct values may vary according
to Ct assays and reference values must be defined for
every assay. Provided these references ranges are clearly
assessed, the indications and usefulness of the high-dose
calcium stimulation test should be very similar to the now
“old “ pentagastrin test.
Conclusions
Evaluation of both basal and stimulated Ct may be useful
in the diagnosis and follow-up of MTC. Even though
ultrasensitive Ct assays have greatly reduced the false
negative rate of a basal Ct measurement when diagnosing
C-cell disease, its sensitivity remains lower than a stimu-
lation test. The calcium stimulation test may be used in
this setting, in particular when basal Ct is in the grey
zone or to detect residual disease or early recurrence
after surgery for MTC in patients with low basal Ct
levels. However, each Ct assay must be evaluated and
each laboratory has to define its own reference ranges for
basal and stimulated values. Further studies are clearly
needed to optimize the Ct thresholds to be used to dis-
tinguish patients with C-cell pathology from normal, and
to better define the patterns of response in particular
conditions, such as in thyroid autoimmune disease and in
renal insufficiency.
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